


# Trial design of MATCH: pros and cons

Keith T. Flaherty, MD  
Massachusetts General Hospital Cancer Center



# Disclosures

Board of Directors: Strata Oncology¥, Scorpion Therapeutics¥


Scientific Advisory Board: Apricity¥, PIC Therapeutics, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, Fog Pharma, Soley Therapeutics, Alterome, intrECate, Immagine

Consultant: Gyges¥, Nextech, Takeda\*, Transcode Therapeutics, Novartis\*, Roche/Genentech\*


¥ Founder

\* NO equity

# NCI-MATCH: investigating therapies beyond tumor types with known benefit



# NCI-MATCH Design



- Metastasis biopsy addresses concern of heterogeneity between primary and metastatic disease
- Uniform diagnostic platform applied across all patient samples
- Imperative to have treatment allocation for as many as possible

# Credentialing Drugs for NCI-MATCH

Level of Evidence	Definition
Level 1	FDA-approved for any indication for that target
Level 2	Agent met a clinical endpoint (objective response, PFS, or OS) with evidence of target inhibition
Level 3	Agent demonstrated evidence of clinical activity with evidence of target inhibition at some level

# Actionable alteration by cancer type

Level 1	FDA-recognized biomarker for an FDA-approved drug in the same indication
Level 2A	Standard of care biomarker for an FDA-approved drug in the same indication
Level 2B	Standard of care biomarker for an FDA-approved drug in another indication
Level 3A	Compelling clinical evidence supporting the biomarker as being predictive of drug response in the same indication
Level 3B	Compelling clinical evidence supporting the biomarker as being predictive of drug response in another indication

